Patent · US Active

Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors

US10322128B2 · kind B2 · utility

2Cited by
0References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 14, 2017
Grant dateJun 18, 2019
Priority date
Expiry dateApr 14, 2037

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.